J. Kevin Buchi
Molecular and Cell Biology
Benitec Biopharma
Australia
Biography
Buchi currently serves as the CEO of TetraLogic Pharmaceuticals a public U.S. Biotechnology company. Prior to that, Kevin served as Chief Executive Officer (‘CEO’) of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (‘Teva’) in October 2011. After the acquisition he served as Corporate Vice President, Global Branded Products of Teva. Kevin joined Cephalon, Inc. in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO. Other Current Directorships of Listed Companies Impax Labs Former Directorships of Listed Companies in last three years Tetralogic Pharmaceuticals Corporation, Stemline Therapeutics, Inc., Forward Pharma A/S, Alexza Pharmaceuticals and Epirus Biopharmaceuticals, Inc.
Research Interest
Molecular and Cell Biology
